Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +6.50p +2.83% 236.50p 318,355 16:27:57
Bid Price Offer Price High Price Low Price Open Price
236.00p 237.00p 236.50p 227.50p 230.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.04 -20.97 -55.70 74.9

Reneuron (RENE) Latest News (1)

More Reneuron News
Reneuron Takeover Rumours

Reneuron (RENE) Share Charts

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart

Intraday Reneuron Chart

Intraday Reneuron Chart

Reneuron (RENE) Discussions and Chat

Reneuron (RENE) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Reneuron trades in real-time

Reneuron (RENE) Top Chat Posts

DateSubject
22/4/2019
09:20
Reneuron Daily Update: Reneuron is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 230p.
Reneuron has a 4 week average price of 71.50p and a 12 week average price of 47.50p.
The 1 year high share price is 261.50p while the 1 year low share price is currently 47p.
There are currently 31,658,664 shares in issue and the average daily traded volume is 575,932 shares. The market capitalisation of Reneuron is £74,872,740.36.
16/4/2019
14:53
jensonbensonjohnson: It's speculation, Lauders, yes, but ... After the April 4th efficacy RNS, Michael Hunt said this: "[...] even though the announcement itself is really more of a *teaser* for data we will be formally presenting in conference in Vancouver at the end of this month" [ Said within first 30 seconds here: [...] ] He's always been straight up; for him to have said that is a really strong indicator of good news to come. Directors/insiders have bought substantial numbers of shares at 225p. They've been given incentives directly related to doubling the share price from these levels. They must believe that's realistic. I've been following RENE for 15+ years and I feel it's changed fundamentally now. I feel very confident that the rises we've seen so far are really just the tip of the iceberg.
15/4/2019
13:18
78steve: Have any of the holders here had a look at STX share price on the rise the company is awaiting US approval for product dealing with iron deficiency. Price said to double on confirmation. Dyor
13/4/2019
04:13
lauders: Https://www.stockopedia.com/articles/reneuron-share-price-hits-a-new-52-week-high-2091/ Making sense of 52 week highs 52 week highs are always good news. But you might be surprised to know that the prices of high performing shares can be slow to move when these companies publish positive earnings news. Studies show it happens because investors are wary about bidding high performing shares any higher (even if they deserve it). This unusual behaviour is down to what the psychologists Amos Tversky and Daniel Kahneman called anchoring-and-adjustment. We form beliefs by using reference points (like share prices). But as new information comes to light (like earnings reports) we're often slow to update our beliefs away from the original anchor point. Evidence shows this tug-of-war usually ends with the ‘new high’ stock actually drifting higher in price over the coming weeks and months. The upward trend is called “post earnings announcement drift”. As the news sinks in, momentum takes over and the price moves higher. A look at Reneuron’s StockReport could offer more insight into what’s driving the momentum in its share price - and whether that might continue. If there is some positive media over the weekend the momentum may continue next week, if not there could be a slight pull back for a few days until people start to "speculate" on the details that could be shared on 26th April: Further read-outs from the patients treated in the Phase 1/2 study will be presented at the 6th Annual Retinal Cell and Gene Therapy Innovation Summit, taking place in Vancouver, Canada, on 26 April 2019. Information regarding this conference may be found at: Https://www.regonline.com/builder/site/default.aspx?EventID=2548135 Also good to see that RENE are being very active when it comes to conferences/events and will be in Kyoto at this event per the website (link below): Https://www.isev.org/page/ISEV2019 Http://www.reneuron.com/news/events/
10/4/2019
14:58
jensonbensonjohnson: I like the incentive conditions: 1) When the Company has signed out-licensing deal(s) for any of its technologies or programmes which, together with other financial resources, provides sufficient funding to allow the achievement of clinical proof of concept data for the CTX and hRPC programmes, one third of the options will vest. 2) When the Company's share price has doubled from the price at the date of grant, one third of the options will vest. 3) When the sixth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest.
08/4/2019
21:31
manc10: this day 5 years ago the share price was 350p today 170p its done well
07/4/2019
16:39
masingi: manc10- I imagine when they decide to quote on NASDAQ. When GWPH did the same the share price increased 5-fold.
04/4/2019
11:15
dickbush: Just checked back. The company had just registered in the US for a trial of its stem cells in stroke patients. That's all it took to get the share price to £48.50. However, including warrant shares, there were only 1.125 mil shares in issue (split adjusted) for a peak market cap of £53.5 mil. Oh, well, back to work. That market cap would be equivalent to £1.69 now...excluding all the Directors options.
06/3/2019
09:08
pdt: The following was posted on the othet board this morning by Cadburyhill; Summary of research note this morn by Stifel is below. "Our investment thesis on ReNeuron is that the stock is fundamentally mispriced and that the delivery of positive clinical data from either of its two main assets will prompt either 1) a long overdue re-rating in the market or 2) industry partners to step in and ascribe value where the market does not. The recent impressive Phase II results with hRPCs in retinitis pigmentosa (RP) has sparked a ~70% share price gain, but in the context of our 625p TP and >60p net cash/share, scenario 1 may be starting to play out but there is a long way to go yet. Meanwhile, we expect industry partners, that were interested in licensing the hRPC asset last year, will be evaluating the asset more intensely now in light of the data, while recent M&A activity in the retinal (gene therapy) space - Roche's $4.3bn acquisition of Spark Therapeutics and Biogen's $800m purchase of Nightstar Therapeutics - demonstrates the value that industry players are currently placing on novel (retinal) technologies. Yet ReNeuron's retinal cell approach has much broader potential applicability than mutation-specific gene therapy. Scenario 2 may play out before scenario 1 can take hold. Reiterate Buy." It will be disappointing if it is taken out before value is realised. Woodford has the largest holding but he purchased a lot of that at 500p so not sure he would want to exit at this level after waiting so long ??
05/3/2019
14:12
pdt: If Invesco managed to dispose of a 10% holding and the share price rises 35% there must be quite a demand for the equity :)
24/1/2019
10:31
philh75: Hi Rayrac, True. But that's only 12-14 months away. And the facts are: 1. In mid-2019, we expect results from the eye trial. 2. IF data is good, Reneuron has a number of suitors who are interested in cutting a deal. We know this because they already had one willing to part with $2.5m for 3 months exclusivity just to talk. 3. Because of the ridiculously low share price (50p), any cash injection from an upfront deal fee for the eye drug, say $20m (educated guess based on the $2.5m for 3 months talking), would massively increase our cash runway. So the market would respond (I think significantly) to the reduction in risk. 4. Edison currently have a forecast of 608p (10 bagger+ from here), which would be higher when we got the assurance of deal in the bag. 5. Following on from the eye results, a mere ~8 months later you have the Stroke results, an the potential for another deal. It is risky IF the data for both trial doesn't turn out possible. But the upside is significant. As ever, DYOR.
Reneuron share price data is direct from the London Stock Exchange
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190423 00:08:39